ADMA Biologics (ADMA) vs Biohaven (BHVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
ADMA Biologics (ADMA) has outperformed Biohaven (BHVN) over the past year, losing 29.7% versus a loss of 29.9%. ADMA Biologics is the larger company by market cap ($2.32 billion vs $1.82 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | BHVN |
|---|---|---|
| Share price | $10.36 | $12.08 |
| Market cap | $2.32B | $1.82B |
| 1-day change | +0.29% | +1.26% |
| YTD return | -43.20% | +7.00% |
| 1-year return | -29.72% | -29.89% |
| 5-year return | +841.82% | — |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | — |
| EPS (TTM) | $0.70 | $-4.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | — |
| Revenue growth (YoY) | +19.63% | — |
| Net income (latest FY) | $146.93M | $-738.82M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | — |
| Net margin | 28.80% | — |
| 52-week high | $20.46 | $18.57 |
| 52-week low | $7.21 | $7.48 |
| Distance from 52-week high | -49.36% | -34.93% |
| Analyst consensus | none | buy |
| Avg. price target upside | +64.09% | +76.08% |
| Average volume | 2.67M | 2.61M |
| Shares outstanding | 223.98M | 151.04M |
| Employees | 640 | 274 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
ADMA vs BHVN FAQ
Which is bigger, ADMA Biologics or Biohaven?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.32B compared with $1.82B for Biohaven (BHVN).
Which stock has performed better over the past year, ADMA or BHVN?
ADMA returned -29.72% over the past 12 months, compared with -29.89% for BHVN (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Biohaven in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Biohaven.